Interestingly, the patent also seems to conceive of a mouse mode for a more traditional controller. While the design of the ...

Novo Nordisk has reported 22% weight loss in people who received weekly amycretin injections for 36 weeks, triggering an 11% jump in the Danish drugmaker’s share price in premarket trading.

Novo is under pressure to boost its development credentials in its rivalry with Zepbound-maker Eli Lilly after a late-stage trial read-out on another next-generation obesity drug known as ...

Why it matters: Novo has struggled to stay competitive with Eli Lilly LLY in developing the next generation of obesity drugs that could improve on Lilly’s Zepbound, with disappointing data for ...

providing a boost for Novo as companies race to develop next-generation obesity treatments. Shares of Novo were up more than 10% on Friday morning. Novo said that patients on a high dose of ...

What's replacing it and the new trends to watch. Plus, welcome Generation Beta! That's the new class of kids born in 2025. The wild predictions for their future and why parents might have to save ...

Copyright 2025 The Associated Press. All Rights Reserved. The U.S. is inching closer and closer to a potential TikTok ban, putting millions of users and content ...

Read daily effectiveness insights and the latest marketing news, curated by WARC’s editors. Send colleagues a link to this content.

Horse's 2023 spinoff as a subsidiary and its production expansion thereafter appear to have come at the right time, as hybrids have been gaining in popularity. After years of electric vehicles ...

The list of 15 medicines includes blockbuster drugs from Novo Nordisk, Pfizer, Bristol Myers Squibb, AstraZeneca, GSK and other companies. Novo’s booming semaglutide franchise for diabetes and ...